

Corrado Ficorella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7641204/publications.pdf>

Version: 2024-02-01

67
papers

1,104
citations

471509

17
h-index

454955

30
g-index

67
all docs

67
docs citations

67
times ranked

1907
citing authors

#	ARTICLE	IF	CITATIONS
1	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. <i>Clinical Lung Cancer</i> , 2019, 20, 237-247.e1.	2.6	118
2	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. <i>European Journal of Cancer</i> , 2020, 128, 17-26.	2.8	85
3	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. <i>European Journal of Cancer</i> , 2021, 142, 18-28.	2.8	81
4	Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1 α functional interplay. <i>International Journal of Oncology</i> , 2014, 44, 2121-2131.	3.3	64
5	Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study. <i>Scientific Reports</i> , 2020, 10, 1456.	3.3	64
6	Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A hypothesis generator-preliminary report. <i>Thoracic Cancer</i> , 2019, 10, 347-351.	1.9	54
7	A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. <i>Oncotarget</i> , 2017, 8, 56921-56931.	1.8	53
8	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression \geq 50% and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2.	2.6	50
9	Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy. <i>Thoracic Cancer</i> , 2018, 9, 1623-1630.	1.9	38
10	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIA study. <i>Immunotherapy</i> , 2018, 10, 1229-1239.	2.0	38
11	The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 190-202.	4.4	24
12	Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. <i>Journal of Cancer</i> , 2019, 10, 5926-5934.	2.5	24
13	Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021, 150, 224-231.	2.8	24
14	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience. <i>Journal of Cellular Physiology</i> , 2019, 234, 7708-7717.	4.1	21
15	Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter SLAVE Study. <i>Cancers</i> , 2020, 12, 1259.	3.7	19
16	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. <i>Journal of Cellular Physiology</i> , 2020, 235, 7900-7910.	4.1	19
17	Post-progression outcomes of NSCLC patients with PD-L1 expression \geq 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. <i>European Journal of Cancer</i> , 2021, 148, 24-35.	2.8	19
18	Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice. <i>Clinical Colorectal Cancer</i> , 2012, 11, 229-237.	2.3	18

#	ARTICLE	IF	CITATIONS
19	Influenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2). , 2021, 9, e002619.		17
20	Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer. Bone, 2016, 87, 169-175.	2.9	16
21	Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. Immunotherapy, 2020, 12, 151-159.	2.0	16
22	Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the <i>FAMI-L1</i> study. Immunotherapy, 2018, 10, 643-655.	2.0	15
23	Survivorship in young women after early breast cancer: a cross-sectional study of emotional traits along 3-years perspective. Rivista Di Psichiatria, 2019, 54, 160-167.	0.6	14
24	Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. Lung Cancer, 2020, 150, 123-131.	2.0	13
25	Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future. Cancers, 2020, 12, 2598.	3.7	11
26	Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice. BioMed Research International, 2014, 2014, 1-11.	1.9	10
27	Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen. International Journal of Oncology, 2014, 44, 1820-1830.	3.3	10
28	Topical menthol for treatment of chemotherapy-induced peripheral neuropathy. Indian Journal of Palliative Care, 2017, 23, 350.	1.0	10
29	P16 hypermethylation contributes to the characterization of gene inactivation profiles in primary gastric cancer. Oncology Reports, 2003, 10, 169-73.	2.6	10
30	Increased expression and activity of p75NTR are crucial events in azacitidine-induced cell death in prostate cancer. Oncology Reports, 2016, 36, 125-130.	2.6	9
31	Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2365-2373.	2.5	9
32	What cancer patients actually know regarding medical cannabis? A cross-sectional survey with a critical analysis of the current attitudes. Journal of Oncology Pharmacy Practice, 2019, 25, 1439-1444.	0.9	9
33	Integrating Oncology and Palliative Home Care in Italy: The Experience of the "L'Aquila per la Vita" Home Care Unit. Tumori, 2013, 99, 225-228.	1.1	8
34	<p>Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice</p>. OncoTargets and Therapy, 2019, Volume 12, 2159-2170.	2.0	8
35	Cliniciansâ€™ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life" Case-Control Study. Clinical Colorectal Cancer, 2021, , .	2.3	8
36	The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. Scientific Reports, 2021, 11, 13770.	3.3	8

#	ARTICLE	IF	CITATIONS
37	Rapid Resolution of Refractory Chemotherapy-Induced Oral Mucositis With Platelet Gel-Released Supernatant in a Pediatric Cancer Patient: A Case Report. <i>Journal of Pain and Symptom Management</i> , 2014, 48, e2-e4.	1.2	7
38	New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting. <i>Cancer Medicine</i> , 2016, 5, 2232-2239.	2.8	7
39	Cancer Care After Natural Disaster: Different Countries, Similar Problems. <i>Journal of Global Oncology</i> , 2019, 5, 1-2.	0.5	7
40	The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1513-1527.	2.2	7
41	Multicentric retrospective analysis of platinum+epemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A snapshot from clinical practice. <i>Thoracic Cancer</i> , 2018, 9, 241-252.	1.9	6
42	Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis. <i>Oncotarget</i> , 2017, 8, 72031-72043.	1.8	6
43	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110598.	3.2	6
44	KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease. <i>Human Pathology</i> , 2018, 74, 178-182.	2.0	5
45	Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial. <i>International Journal of Medical Sciences</i> , 2021, 18, 2245-2250.	2.5	5
46	The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study. <i>Palliative and Supportive Care</i> , 2019, 17, 82-86.	1.0	4
47	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020, 146, 1917-1929.	5.1	4
48	The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings. <i>Palliative and Supportive Care</i> , 2020, 18, 33-38.	1.0	4
49	Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series. <i>Journal of Addictive Diseases</i> , 2020, 38, 229-234.	1.3	4
50	Timed flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOX regimen. <i>Oncology Reports</i> , 2018, 40, 803-812.	2.6	3
51	Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer. <i>Cancers</i> , 2020, 12, 2457.	3.7	3
52	A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale. <i>Future Oncology</i> , 2022, 18, 771-779.	2.4	3
53	Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab. <i>Journal of Clinical Neuromuscular Disease</i> , 2018, 20, 99-100.	0.7	2
54	Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 1094-1101.	1.3	2

#	ARTICLE	IF	CITATIONS
55	Comment on "What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain: Expert Opinion". <i>Drugs</i> , 2016, 76, 1059-1061.	10.9	1
56	Family history of cancer and DNA damage response genes: Two sides of the same coin?. <i>Thoracic Cancer</i> , 2019, 10, 401-401.	1.9	1
57	Rare bone toxicity associated with vismodegib. <i>JAAD Case Reports</i> , 2020, 6, 482-485.	0.8	1
58	Sequencing chemotherapy and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (UC): Meet-Uro1 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16013-e16013.	1.6	1
59	A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2020, 12, 6107-6111.	1.4	1
60	Integration between Oncology and Palliative Care: A Plan for the Next Decade?. <i>Tumori</i> , 2017, 103, e23-e23.	1.1	0
61	Where are we with treatment options after first line in small cell lung cancer? A report of two opposite cases treated with CAPTEM regimen and possible perspectives. <i>Journal of Thoracic Disease</i> , 2018, 10, E520-E525.	1.4	0
62	"Palliative" or "Supportive": Is It Just a Matter of Word?. <i>Journal of Palliative Medicine</i> , 2018, 21, 1546-1546.	1.1	0
63	Clinical and psychometric validation of the BreSAS questionnaire module for symptom assessment among breast cancer survivors. <i>Supportive Care in Cancer</i> , 2020, 28, 1051-1058.	2.2	0
64	Different clinical outcome of metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (Flr-B/FOx) according to KRAS genotype and disease extension.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14010-e14010.	1.6	0
65	c.35 G > A KRAS-mutant genotype and clinical outcome of patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 512-512.	1.6	0
66	Intensive first-line triplet chemotherapy plus cetuximab Flr-C/FOx-C in RAS wild-type MCRC: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 673-673.	1.6	0
67	First-line chemotherapy with docetaxel, oxaliplatin, and timed-flat infusion 5Fluorouracil in metastatic gastro-esophageal adenocarcinomas: The experience with FD/FOx regimen.. <i>Journal of Clinical Oncology</i> , 2018, 36, 178-178.	1.6	0